<<

Contents

€ € Tumors of blood vessels € Heart failure € Ischemic heart disease Sakchai Chitpakdee, M.D. € Valvular heart diseases € Rheumatic heart disease € Infective endocarditis € Myocarditis € Pericardial diseases

Arteriosclerosis

€ = hardening of the y ○ Large & medium size vessels y Monckeberg medial calcific sclerosis ○ Medium size vessels with tunica media calcification y Arteriolosclerosis ○ Small arteries/

Atherosclerosis

€ “intimal lesion”: or fibrofatty plaques or atheromatous plaques” € Large and medium size arteries y Raised focal plaque within the intima y Core lipid (/cholesterol esters) and a covering fibrous cap y Cells: foamy cells (macrophage/SMC), lymphocytes Atherosclerosis

€ Complicated lesion: y Calcification y Rupture/ulceration -> atheroemboli, thrombus y Hemorrhage y y Aneurysmal dilation

Atherosclerosis

€ Epidemiology & risk factors: y Age: middle or later age y Sex: pre-menopause -> M > F 60s to 70s -> M = F y Genetics: familial y Hyperlipidemia: high cholesterol/TG & ↓ HDL y y Cigarette smoking y Diabetes mellitus

Atherosclerosis Clinical features & prevention

€ Epidemiology & risk factors: € Clinical features: y Elevated plasma homocysteine y Ischemic/infarction of organs y Other factors: y Atherosclerotic ○ Competitive stressful lifestyle: type A personality € Prevention: ○ Lack of exercise y Primary prevention: risk factor modification ○ y Secondary prevention: prevent recurrence of y Moderate intake of alcohol -> protective events or complications (antiplatlet drugs etc) factor Tumors Tumors

€ Benign neoplasms: € Intermediate-grade neoplasms: y : , cavernous, pyogenic y Kaposi sarcoma granuloma y Hemangioendothelioma y Lymphangioma: simple (capillary), cavernous lymphangioma (cystic hygroma) € Malignant neoplasms: y Glomus tumor, myopericytoma y Angiosarcoma y Vascular ectasia: flammeus, spider y Hemangiopericytoma (benign & malignant) , hereditary hemorrhagic telangiectasia (osler-Weber-Rendu dis.) y Bacillary : B. henselae

Hemangioma Hemangioma

€ Pyogenic granuloma (lobular capillary) € Capillary hemangioma: y Polypoid nodules of , gingiva, oral y Skin, , oral cavities of head mucosa and neck, lung, liver, kidney y Bleeding, ulcerated y Strawberry type (juvenile hemangioma): 1:200 y Granuloma gravidarum: 1% pregnant newborns: fade 1-3 yr, regress by 7 yr women, pyogenic granuloma at gingiva, € : regress after delivery y Older age, less circumscribed, deeper y No regress

Lymphangioma

€ Lymphangioma circumscriptum (capillary ymphangioma) y Subcutaneous mass of head and neck € Cavernous lymphangioma y Cystic hygroma y Neck and axilla of children y Turner syndrome: neck region Vascular ectasia Kaposi sarcoma

€ Nevus flammeus: € Chronic, classic european KS y Birthmark of head and neck, flat € Lymphadenopathy, African, endemic KS y Pink to purple Æ regress € Transplant-associated € Port-wine stain: no regress (immunosuppression-associated) KS y Trigeminal nerve Æ Sturge-Weber syndrome (ecephalotrigemina € AIDS-associated KS angiomatosis), venous mass of € Clinical: patchesÆ plaquesÆ nodules leptimeninges Æ seizure, hemiplegia, mental retardation € Cause: HSV-8, HIV?

Angiosarcoma

€ Malignant endothelial neoplasms € Skin, soft tissue, breast, liver € Cause: y Breast: radiation, lymphedema y Liver: polyvinyl chloride (PVC), throrotrast y Skin: arsenic (pesticide)

Heart failure Left-side heart failure

€ Cause: IHD, HT, aortic & mitral valve € CHF = congestive heart failure disease, cardiomyopathy € Common end result of many forms of HD € Clinical: € Unable to pump blood at rate of body y Forward effect: poor organ perfusion requirement (prerenal azotemia, hypoxic € Progressive deterioration of myocardial encephalopathy) contraction y Backward effect: pulmonary edema y Systolic dysfunction (dyspnea, orthopnea, PND) y Diastolic dysfunction Right-side heart failure What is Ischemic Heart Disease?

€ Cause: pulmonary HT (cor pulmonale) € Myocardial € Hypertrophy of right ventricle, atrium, € Imbalance btw supply (perfusion) & demand of septum Æ left-side HF oxygenated blood € Clinical: € Ischemia Æ ↓Oxygen y Forward effect: poor oxygenation Æ ↓ Nutrient substrates y Backward effect: organ edema, effusion Æ ↓ Metabolites removal € Ischemia Æ Dysfunction of pumping Æ Abnormal heart rhythms Æ Myocardial infarction (Necrosis)

Etiology of IHD Clinical manifestation

€ 90 % Æ coronary Four syndromes: atherosclerosis 1. Myocardial infarction 2. Angina pectoris: variants y Atherosclerosis Æ narrow lumen 1. Stable angina Æ thrombus formation 2. Prinzmetal angina Æ coronary vasospasm 3. Unstable angina 3. Chronic ischemic heart disease € Others: hypertrophy, hypovolemia, 4. Sudden cardiac death hypoxemia,↑ heart rate

Clinical manifestation Role of fixed coronary obstruction

€ At least 75 % reduction of cross- € Stable plaque Æ Unstable plaque sectional area (insufficient compensatory Stable angina Æ Acute coronary vasolidation) syndromes € At least 90 % reduction Æ ischemia at rest € Acute coronary syndromes: € Atherosclerosis type IV-VI unstable angina, acute MI, and € Affected location: proximal (LAD, LCX), sudden death entire (RCA) Role of acute plaque change

€ Acute plaque change/disruption: y Hemorrhage into Æ ↑ volume y Rupture or fissuring Æ Thrombosis y Erosion or ulceration Æ Thrombosis

A = Plaque rupture B = Thrombus over plaque rupture C = Massive plaque rupture with thrombus

Angina pectoris Angina pectoris

€ Paroxysmal and usually recurrent attacks of € Stable angina: substernal or precordial chest discomfort caused by y Most common, and predictable transient (15 sec to 15 min) myocardial ischemia y Reduction of coronary perfusion by chronic that falls short of inducing cellular necrosis (infarct) stenosing coronary atherosclerosis € Three patterns: y Pain brought by physical excertion, emotional y Stable or typical angina stress, heat or cold fever, anemia etc y Prinzmetal or variant angina y Pain relieved by rest (decreased demand) or y Unstable or crescendo or accelerating or nitroglycerin (vasodilator) preinfarction angina y Monitoring ECG: ST segment depression or elevation or T-wave inversion

Angina pectoris Angina pectoris

€ Prinzmetal variant angina: € Unstable angina: y Uncommon, and unpredictable y Angina occurring with increasing frequency, y Occur at rest not related to physical and emotional precipitated with less effort, often occurs at exertion rest and tends to be prolonged duration y Coronary artery vasospasm y Most induced by disruption of atherosclerotic plaque with partial thrombosis and possibly y Atherosclerosis-induced hypercontractility, embolization or vasospasm vasospastic chemicals secretion by mast cells and abnormal calcium influx y Harbinger of subsequent acute MI y Response well to calcium-channel blockers and y Thrombus labile and lasts 20 to 30 minutes nitroglycerin y 10 to 15% total occlusion Å collateral vessel y ECG: elevation of ST-segment Myocardial infarction Myocardial infarction

€ Necrosis of myocardium € Transmural (Q-wave) infarction € Prolonged period of ischemia at rest lasting > y Full or nearly full thickness necrosis 20 min, unresponsive to NTG y Acute plaque change + completely obstructive € Ischemic ECG change and positive cardiac thrombosis (fixed and persist > 1 hour) enzymes y ECG: ST segment elevation Æ Q wave € Subendocardial (Non-Q-wave) infarction € 25 % silent: old age, diabetics y 1/3 to ½ inner ventricle thickness necrosis € Subendocardial VS Transmural infarction y Incomplete obstructive thrombosis (>30-40 min) y Non-Q-wave VS Q-wave infarction y ¼ complete obstruction + collateral supply y ECG: ST segment elevation Æ Non-Q-wave

Morphological change

€ Almost all transmural MI involve at least a portion of left ventricle € and MI site: y LAD (40-50%) -> ant wall of LV, apex, ant portion of ventricular septum y RCA (30-40%) -> inf-post wall of LV, post portion of ventricular septum, RV (inf-post) y LCX (10-20%) -> lateral wall LV except apex

1 day 3 to 4 days

7 to 10 days 3 weeks Evolution of morphology change Cardiac enzymes Time Morphology change 0 - ½ hours Ultrastructural change (EM) € Released enzymes after myocardial cell

2 – 3 hours Triphenyltetrazolium chloride dye: dead: noninfarct area Æ brick-red, infarcted Æ unstained y Myoglobin 4 – 24 hours Gross: dark mottling area, y Troponin (TnI and TnT) Histology: hemorrhage and necrosis y Creatine kinase (total CK and CK-MB) 1 – 7 days Gross: yellow-tan mottling, reddish border Histology: neutrophils and macrophages y LDH (LDH1, LDH2) 7 – 14 days Gross: red-tan margin Histology: macrophages and granulation tissue 2 – 8 weeks Gross: gray-white scar Histology: collagen deposition > 2 months Scarring complete

Cardiac enzymes Consequences and complications

7x Myoglobin 6x Total CK € 50 % AMI Æ dead € Half of dead occur within 1 hour (VF) 5x € In-hospital death rate 30% Æ 10-13 % 4x € 75 % develop one or more complications LDH 3x y Contractile dysfunction Æ cardiogenic shock 10 – 15 % of AMI and 70 % mortality rate 2x CK-MB Troponin I y Arrhythmias Æ sudden death Upper limit of normal serum level of normal limit Upper 1x bradycardia, tachycardia, VPC, VT, VF asystole 0 20 40 60 80 100 120 140 160 Hours from onset of infarction

Consequences and complications Consequences and complications

€ Ventricular aneurysm Æ thrombus, € Myocardial rupture: arrhythmias, heart failure, rupture y Ventricular free wall Æ cardiac temponade € Papillary muscle dysfunction Æ MR y Ventricular septum Æ left-to-right shunt € Progressive late heart failure y Papillary muscle Æ acute MR € Pericarditis € Infarct extension and expansion € Mural thrombus Æ thromboembolism Apical left ventricular Rupture ventricular aneurysm septum

Wall thinning and Rupture papillary mural thrombus muscle

Cardiac rupture Fibrinous Pericarditis

Prognosis Treatment

€ Extent and location of infarction € Decrease myocardial oxygen demand € Quality of left ventricular function € Increase myocardial oxygen supply € Monitoring and treat € Previous cardiovascular health € Decrease myocardial oxygen demand: € Age, female gender & other diseases y Preload & afterload reduction € Total mortality for 1st year = 30 % y HR control, pain relief, activity restriction € 3 – 4 % mortality with each passing year € Increase oxygen supply: y Oxygen administration y Antiplatelet therapy (aspirin), thrombolytic drug y (PTCA), atherectomy, CABG

Infarct modification after reperfusion : Enzymatic digestion of thrombus to open lumen € Early reperfusion: y Salvage ischemic myocardium (15-20 min) Percutaneous y Limit infarct size (after longer interval) transluminal coronary angioplasty € Critical period: first 3 – 4 hours (PTCA): Physical disruption of € Thrombolytic Rx: streptokinase, and tissue plaque to open lumen type plasminogen activator (tPA), reteplase (rPA) Coronary artery bypass grafting € PTCA: eliminate thrombus and relieve some (CABG): underlying atherosclerotic plaque Surgical placement of a new conduit to bypass occlusion Chronic ischemic heart disease Sudden cardiac death

€ Progressively develop heart failure as a € Unexpected death from cardiac causes consequence of ischemic myocardial damage early (usually within 1 hour) € Ischemic cardiomyopathy € Causes: y After MI Æ cardiac decompensation of y Majority IHD hypertrophic noninfarcted myocytes y Others: congenital structural or coronary arterial y No MI Æ severe obstructive coronary disease abnormalities ○ Aortic valve , mitral valve prolapse Æ diffuse myocardial dysfunction ○ Myocarditis ○ Dilated and hypertrophic cardiomyopathy € Mechanism: arrhythmia (Asystole, VF)

Endocardial and valvular diseases Major causes

€ Stenosis = failure of a valve to open € Mitral valve stenosis: completely y Postinflammatory scarring (RHD) € Mitral valve regurgitation: y Abnormalities of leaflets and commissures € Regurgitation/Insufficiency = Inability of ○ Postinflammatory scarring a valve to close completely ○ Infective endocarditis ○ Floppy mitral valve (Prolapse) y Abnormalities of tensor apparatus ○ Rupture of papillary muscle/cordae tendinae

Major causes

€ Aortic stenosis: y Postinflammatory scarring (RHD) y Senile calcific aortic stenosis y Calcification of a congenitally deformed valve € Aortic regurgitation y Postinflammatory scarring y Infective endocarditis y Aortic diseases: Syphilitic , Marfan syndrome, Rheumatoid arthritis Disorders of Mitral valve

€ Mitral stenosis: y Abnormal Lt. atrial-Lt. ventricular pressure gradient during diastole y Atrial enlargement and hypertrophy y SevereÆ PHT, Rt. Ventricular hypertrophy, Rt. HF y Clinical: Dyspnea, orthopnea, weakness, Dysarrhythmia (AF) Æ emboli

Disorders of Mitral valve Disorders of Aortic valve

€ Mitral regurgitation: € Aortic stenosis: y Elevation of Lt. atrial volume and pressure y Lt. ventricular-aortic pressure gradient y Lt. atrial and ventricle dilate and hypertrophy y Lt. ventricular hypertrophy y Severe: Lt. HF, pulmonary congestion y Severe: myocardial ischemia, Lt. HF y Clinical: Anginal pain, syncope, fatigue and low systolic

Rheumatic fever and Rheumatic heart Disorders of Aortic valve disease

€ Aortic regurgitation: € Rheumatic fever: y Lt. Ventricle volume overload y acute, immunologically mediated y Lt. Ventricular hypertrophy and dilation multisystem inflammatory disease y Severe: Lt. HF y occurs a few weeks after an episode of group A (beta-hemolytic) streptococcal y Clinical: palpations, trobbing heart (large stroke volume) pharyngitis y acute rheumatic carditis may progress to chronic valvular deformities Rheumatic fever- Diagnosis Jones criteria

€ Jones criteria: € Major criteria: y 2 major criteria or y Carditis y 1 major and 2 minor criteria y Polyarthritis (Migratory) plus y Chorea (Sydenham) y evident of antecedent group A y Erythema marginatum of skin streptococcal infection y Subcutaneous nodules ○ positive throat culture ○ positive group A strep. antigen test ○ elevated serum anti-strep. antibody titer

Jones criteria Rheumatic heart disease

€ Minor criteria: € Acute rheumatic fever: Carditis y Clinical findings: y Endocarditis, myocarditis, pericarditis ○ Arthralgia y Pancarditis ○ Fever y Aschoff bodies, Antischkow cells (Pathognomonic), Aschoff giant cells y Laboratory findings: € Chronic rheumatic heart disease: ○ Elevated acute phase reactant (ESR,CRP) y deformed fibrotic valves (MV>AV>TV>PV) ○ Prolonged PR interval on ECG y Frequent cause of MS (99% of cases)

Pathogenesis

€ hypersensitivity reaction induced by group A streptococcal € Streptococcal antigens (M protein) that cross-react with human tissue through molecular mimicry € Most ARF-associated strains: M type 3, 1, 18, 5 and 6 € M protein: antiphagocytic surface antigens Clinical Features Treatment

€ ARF occurs 10 days to 6 weeks (usu. € anti-streptococcal therapy: within 3 wks) after pharyngitis y IM benzathine € most often in children age of 5 to 15 y 10 days oral penicilin or erythromycin years old € anti-inflammatory therapy: € 1/3 of ARF patients has no history of y oral salicylates previous pharyngitis y corticosteroid (prednisolone) with severe € Serologic study: antistreptolysis-O cases of carditis (ASO) or antideoxyRNase B (anti- € Prophylaxis: antibiotics given 5 yrs to DNase B) titer lifetime prophylaxis

Infective endocarditis Infective endocarditis

€ caused by invasion and colonization of € Acute endocarditis: endocardial structures by y destructive infection, frequently in normal heart microorganisms which resulting in valve, with highly virulent organisms y leads to death within days or weeks of > 50% y bacteria (most common): bacterial of patients endocarditis € Subacute endocarditis: y fungi, rickettsiae () and clamydiae: y infection with low virulent organisms in uncommon abnormal heart y disease appears insidious and protracted course

Cause and Pathogenesis Cause and Pathogenesis

€ Cardiac and vascular abnormalities: € Host factors: y rheumatic heart disease y neutropenia y myxomatous mitral valve (MVP) y immunodeficiency y degenerative calcified valvular stenosis y therapeutic immunosuppression y bicuspid aortic valve y diabetic mellitus y artificial (prosthesis) valves y alcohol y vascular grafts y intravenous drug abuse Cause and Pathogenesis

€ Causative organisms: ○ alpha-hemolytic (viridans) streptococci (50- 60%) ○ S. aureus (10-20%) ○ HACEK group: , , Cardiobacterium, Eikenella and Kingella) ○ S. epidermidis in prosthetic valve ○ 10% Æ culture negative endocarditis y previous antibiotic therapy y difficult to culture or deep enbedded organism

Cause and Pathogenesis Clinical features

€ Portal of entry: € Subacute endocarditis y dental or surgical procedure y Fever (Prolonged) y infection at other site y non-specific symptoms: fatigue, flulike syndrome y injection eg. IVDUs y Murmurs (90% in left-side disease) y occult sources from gut, oral cavity, or y Others: petechiae, subungual hemorrhage, trivial injuries Roth spots in the eyes (microemboli) € Acute endocarditis: fever, chills, Æ antibiotic prophylaxis weakness, murmur, CHF

Complications

€ Cardiac complications: y valvular insufficiency or stenosis y cardiac failure y myocardial ring abscess with perforation y suppurative pericarditis y prothesis valve leakage or dehiscence € Embolic complications: y Left-side: brain, MI, spleen, kidneys y Right-side: lung infection Myocarditis Causes of myocarditis

€ Inflammatory process of the € : myocardium resulting in injury of cardiac y Viruses: Coxsackies virus, ECHO, influenza, HIV, CMV myocytes y Clamydiae: C. psittaci € Causes: y Rickettsiae: R. typhi fever y infections y Bacteria: Diphtheria, N. Meningitidis, Borrelia Lyme disease y Immune-mediated y Fungi: Candida y others: sarcoidosis, giant cell myocarditis y Protozoa: Trypanosoma chagas disease, toxoplamosis y Helminths: trichinosis

Causes of myocarditis

€ Imune-mediated reactions: y Postviral y Poststreptococcal (rheumatic) y SLE y Drugs: Methydopa, sulfonamides y Transplant rejection € Unknown causes: y sarcoidosis y Giant cell myocarditis

Clinical features Pericardial effusion

€ Asymptomatic Æ complete recovery € Accumulation of noninflammatory fluid in the pericardial sac (normal 30 – 50 mL € Arrhythmias of fluid) € Cardiomegaly Æ functional valvular € Cardiac tamponade = external regurgitation compression of the heart chambers € Heart failure Æ death resulting in filling impair € Develop DCM years later y Æ ↓ stroke volume, HR ↑ y Rx: pericardiocentesis € Diagnosis: endomyocardial biopsy Pericarditis

€ Inflammation of the pericardium € Acute pericarditis: y Serous/ fibrinous/ purulent/ hemorrhagic/ caseous y Fever, tachycardia, , pericardial friction rub € Chronic pericarditis: y Constrictive pericarditis/ adhesive mediastinopericarditis

References

1. Ramzi S. Cotran: Robbins’ Pathologic Basis of disease, 6th ed. Philadelphia, WB Sauders, 1999 2. Copstead Banasik: Pathophysiology biological and behavioral perspective, 2nd ed 3. Baunwald: Heart disease: A textbook of Cardiovascular Medicine, 6th ed. Philadelphia, WB Sauders, 2001 4. Eugene Braunwald: Cardiovascular diseases: Harrison’s Manual of Medicine, 15th ed. McGraw- Hill, 2002